Nectin-4 ADC 9MW2821

Zhang, Jian; Liu, R.; Yang H.; Gao, S. P.; Li, X.; Chen, J.; Gong, X. Z.; Li Y.; Li, X. J.; Liu, J. J.; Zhang, M. M.; Lou, Z. H.; Guo, H. Q.; Hu B.; Xu, D. L.; Zhang, S. X.

Nectin-4 ADC 9MW2821

ORR 54.1% in urothelial cancer

A next-generation ADC targeting Nectin-4 with notable antitumor activity in pretreated advanced solid tumors, especially urothelial cancer.

Zhang, Jian · Liu, R. · Yang H. · Gao, S. P. · Li, X. · Chen, J. · Gong, X. Z. · Li Y. · Li, X. J. · Liu, J. J. · Zhang, M. M. · Lou, Z. H. · Guo, H. Q. · Hu B. · Xu, D. L. · Zhang, S. X.

Annals of Oncology 2025

Specifications

期剂量: {'zh': '1.25', 'en': ''} mg/kg

Advantages

ORR 54.1% in urothelial cancer

ORR 32.1% in cervical cancer

ORR 50% in triple negative breast cancer